TYAN Showcases HPC, AI and Storage Server Platforms Featuring 2nd Gen Intel® Xeon® Scalable Processors at SC19
19.11.2019 17:00:00 EET | Business Wire | Press release
TYAN®, an industry-leading server platform design manufacturer and a subsidiary of MiTAC Computing Technology Corporation, exhibits a broad selection of HPC, AI, storage and cloud server platforms that are optimized for enterprise and data center markets at SC19 through November 21st, Booth # 1601 in Denver’s Colorado Convention Center.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005008/en/
TYAN HPC Server Platforms Boost Performance with 2nd Gen Intel Xeon Scalable Processors for Enterprises and Data Centers (Photo: Business Wire)
“Data is the foundation of the new economy, and how organizations effectively move, store and process will help determine their level of success,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “By leveraging the 2nd gen Intel® Xeon® Scalable processors, TYAN’s leading portfolio of HPC, storage and cloud server platforms enable to help our customers accelerate innovation, drive business value, and bring products and services to market faster.”
TYAN HPC and Storage Server Platforms Boost Performance with 2nd Gen Intel Xeon Scalable Processors
TYAN’s HPC server platforms are built on the 2nd gen Intel Xeon Scalable processors with the addition of Intel® Deep Learning Boost technology and Intel® Optane™ DC persistent memory that enable to deliver higher performance for a range of HPC and AI applications. The new Thunder HX FT83-B7119 features high CPU-to-GPU bandwidth for various parallel workloads. The 4U system supports 10 double-width PCIe x16 slots for GPU deployment, a single-wide x16 networking card, up to 3TB of system RAM, and its front-loading 24 hot-swap, tool-less 3.5” drive bays enable easy access with simple, tool-free installation.
More HPC platforms on display include, Thunder HX FT77D-B7109 in a 4U two-socket design with integrated Intel® Omni-Path100 gigabit networking fabric for massively parallel workloads such as scientific computing and large-scale facial recognition; Thunder HX FT48T-B7105 in a 4U pedestal workstation design delivering maximum I/O to professional power users for 3D rendering and image processing; Thunder HX GA88-B5631 with high density and performance in a 1U single-socket chassis supporting 12 DIMM slots and 5 PCIe x16 slots for machine learning and artificial intelligence applications.
Powered by 2nd gen Intel Xeon Scalable processors, TYAN storage platforms offer a variety of tiered storage implementation scenarios for data centers and enterprises across a range of Thunder SX FA100-B7118, a 4U 100-bay high-capacity cold storage, Thunder SX TN76-B7102, a 2U server storage with 24 DDR4 DIMM slots and twelve 3.5” hot-swap drive bays for data virtualization and in-memory databases, and the Thunder SX GT62H-B7106, a 1U high-performance all-flash storage with 10 U.2 NVMe drive bays for extremely high speed data streaming applications.
The new Thunder SX GT90-B7113 is a 1U dual-socket high-density storage platform supporting twelve 3.5” hot-swap SATA drives (SAS drives are supported by configuration). mounted to a service drawer and four 2.5” hot-swap NVMe U.2 drive bays in a 35” chassis depth. The platform is designed for CSP server-based software-defined storage applications by allowing serviceability and density within the same server.
TYAN also showcases entry server platforms highlighting Intel® Xeon® E-2200 processors to offer professional-grade performance. The Thunder CX GT24E-B5556 is a 1U server optimized for cost-effective cloud gaming applications with support for up to 4 DDR4 DIMM slots, 1 double-width GPU card, and dual 10GBase-T Ethernet ports; the Thunder CX GX38-B5550 is a 1U compact sever with sub-400mm deep chassis and support for two 3.5" internal SATA drive bays for edge computing.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005008/en/
Contact information
MiTAC Computing Technology Corporation/ TYAN Business Unit
Fenny Chen
fenny.chen@tyan.com.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom